StuartQuin

Stuart is a seasoned healthcare operator and investor with nearly two decades of experience both within private equity principally at 3i, and in healthcare leadership across Diagnostic and Pharmaceutical services.

Stuart currently sits on the boards of Sterling Pharma and Genesis Research Group.

Stuart previously served as Chief Executive Officer at Medica Group PLC, the UK’s leading teleradiology services company. During his tenure, revenue more than doubled and the company expanded via four acquisitions across the UK, US and Ireland, as well as entering into the imaging market for clinical trials and digital pathology. In July 2023, Medica was sold to IK Partners following a successful delisting from the main London market.

Prior to his role at Medica, Stuart established and later became CEO of Labco’s UK business which was acquired by Cinven and merged with Synlab in 2015 to create the largest clinical laboratory services company in Europe. He expanded UK revenue 7-fold by winning new NHS outsourced diagnostic service contracts and through the acquisition of four companies including those specialising in drug and veterinary testing. At Synlab, he became the Group Chief Commercial Officer and latterly CEO of a fast-growing region spanning 15 countries across Central and Eastern Europe, Middle East and West Africa.

Stuart began his career at Accenture in the health and life sciences strategy consulting practice. He joined 3i plc in 2005 where he managed and executed several healthcare investments.

He holds a BSc (Hons) in Immunology from the University of Edinburgh, a PhD in Immunology from Imperial College, London and an MBA from INSEAD in France/Singapore. Stuart is a Fellow of the Royal Society of Medicine and the Royal Geographical Society.